Literature DB >> 21201524

4-(4-Fluoro-phen-yl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2H)-one.

Simona Margutti, Dieter Schollmeyer, Stefan Laufer.   

Abstract

The crystal structure of the title compound, C(15)H(11)FN(2)O(3), was determined as part of a study on the biological activity of isoxazolone derivatives as p38 mitogen-activated protein kinase (MAPK) inhibitors. The dihedral angles between rings are isoxazole/benzene = 55.0 (3)°, isoxazole/pyridine = 33.8 (2)° and benzene/pyridine = 58.1 (2)°.

Entities:  

Year:  2008        PMID: 21201524      PMCID: PMC2960186          DOI: 10.1107/S1600536807066500

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

Isoxazolones as potent inhibitors of p38 MAP kinases were first described by Laughlin et al. (2005 ▶). For related literature, see: Adams et al. (1998 ▶); Clark et al. (2002 ▶); De Laszlo et al. (1998 ▶); Foster et al. (2000 ▶); Laufer & Wagner (2002 ▶); Laufer et al. (2006 ▶); Ohkawa et al. (2001 ▶); Revesz et al. (2000 ▶); Wang et al. (1998 ▶).

Experimental

Crystal data

C15H11FN2O3 M = 286.26 Tetragonal, a = 10.0828 (6) Å c = 25.257 (5) Å V = 2567.6 (6) Å3 Z = 8 Cu Kα radiation μ = 0.97 mm−1 T = 193 (2) K 0.40 × 0.20 × 0.10 mm

Data collection

Enraf–Nonius CAD-4 diffractometer Absorption correction: multi-scan (MULABS; Blessing, 1995 ▶) T min = 0.60, T max = 0.88 5114 measured reflections 1488 independent reflections 1129 reflections with I > 2σ(I) R int = 0.081 3 standard reflections frequency: 60 min intensity decay: 5%

Refinement

R[F 2 > 2σ(F 2)] = 0.068 wR(F 2) = 0.192 S = 1.00 1488 reflections 191 parameters H-atom parameters constrained Δρmax = 0.45 e Å−3 Δρmin = −0.34 e Å−3 Data collection: CAD-4 Software (Enraf–Nonius, 1989 ▶); cell refinement: CAD-4 Software; data reduction: CORINC (Dräger & Gattow, 1971 ▶); program(s) used to solve structure: SIR92 (Altomare et al., 1994 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997 ▶); molecular graphics: PLATON (Spek, 2003 ▶); software used to prepare material for publication: SHELXL97. Crystal structure: contains datablocks I, global. DOI: 10.1107/S1600536807066500/cf2171sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536807066500/cf2171Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C15H11FN2O3Z = 8
Mr = 286.26F000 = 1184
Tetragonal, P43212Dx = 1.481 Mg m3
Hall symbol: P 4nw 2abwCu Kα radiation λ = 1.54178 Å
a = 10.0828 (6) ÅCell parameters from 25 reflections
b = 10.0828 (6) Åθ = 20–32º
c = 25.257 (5) ŵ = 0.97 mm1
α = 90ºT = 193 (2) K
β = 90ºBlock, yellow
γ = 90º0.40 × 0.20 × 0.10 mm
V = 2567.6 (6) Å3
Enraf–Nonius CAD-4 diffractometerRint = 0.081
Monochromator: graphiteθmax = 69.8º
T = 193(2) Kθmin = 4.7º
θ/2ω scansh = −12→12
Absorption correction: multi-scan(MULABS; Blessing, 1995)k = −12→12
Tmin = 0.60, Tmax = 0.88l = −23→30
5114 measured reflections3 standard reflections
1488 independent reflections every 60 min
1129 reflections with I > 2σ(I) intensity decay: 5%
Refinement on F2Secondary atom site location: difference Fourier map
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.068H-atom parameters constrained
wR(F2) = 0.192  w = 1/[σ2(Fo2) + (0.149P)2] where P = (Fo2 + 2Fc2)/3
S = 1.00(Δ/σ)max < 0.001
1488 reflectionsΔρmax = 0.45 e Å3
191 parametersΔρmin = −0.34 e Å3
Primary atom site location: structure-invariant direct methodsExtinction correction: none
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. Friedel Pairs merged (MERG 3 instruction). The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C10.4167 (4)0.0719 (4)0.3006 (2)0.0248 (11)
C20.3537 (4)0.1885 (4)0.2905 (2)0.0231 (10)
N30.2782 (4)0.1781 (4)0.24613 (17)0.0272 (10)
O40.2804 (4)0.0427 (3)0.23076 (16)0.0346 (9)
C50.3701 (5)−0.0233 (5)0.2641 (2)0.0302 (11)
C60.1515 (5)0.2379 (6)0.2342 (2)0.0366 (13)
H6A0.08060.18550.25050.055*
H6B0.13870.24030.19580.055*
H6C0.14930.32840.24830.055*
O70.3926 (4)−0.1402 (4)0.25595 (18)0.0409 (10)
C80.5231 (4)0.0446 (4)0.3400 (2)0.0262 (11)
C90.6393 (5)0.1185 (5)0.3410 (2)0.0290 (11)
H90.64990.18960.31670.035*
C100.7405 (5)0.0908 (5)0.3767 (3)0.0348 (13)
H100.81980.14150.37740.042*
C110.7207 (5)−0.0138 (5)0.4112 (2)0.0300 (12)
C120.6096 (5)−0.0891 (5)0.4118 (2)0.0315 (12)
H120.6000−0.15980.43640.038*
C130.5100 (5)−0.0603 (5)0.3757 (3)0.0313 (12)
H130.4318−0.11280.37520.038*
F140.8198 (3)−0.0417 (3)0.44649 (16)0.0477 (10)
C150.3631 (4)0.3142 (4)0.31988 (19)0.0198 (10)
C160.3580 (4)0.4384 (4)0.2958 (2)0.0253 (11)
H160.34480.44380.25860.030*
C170.3714 (5)0.5514 (5)0.3240 (2)0.0265 (11)
H170.36550.63470.30660.032*
N180.3934 (4)0.5467 (4)0.37729 (18)0.0253 (9)
C190.3954 (5)0.4264 (5)0.4021 (2)0.0270 (11)
H190.40760.42280.43940.032*
C200.3804 (4)0.3122 (4)0.3746 (2)0.0254 (10)
H200.38170.22980.39290.030*
O210.4120 (4)0.6544 (3)0.40417 (17)0.0395 (10)
U11U22U33U12U13U23
C10.0148 (19)0.020 (2)0.039 (3)0.0011 (17)0.0004 (19)0.000 (2)
C20.022 (2)0.021 (2)0.027 (3)0.0009 (17)0.0007 (19)−0.0004 (19)
N30.033 (2)0.0243 (18)0.025 (2)0.0040 (17)−0.0053 (18)−0.0087 (17)
O40.0338 (19)0.0286 (17)0.041 (2)0.0032 (15)−0.0063 (17)−0.0105 (16)
C50.025 (2)0.022 (2)0.043 (3)0.0028 (19)0.004 (2)−0.004 (2)
C60.036 (3)0.041 (3)0.033 (3)0.010 (2)−0.011 (2)0.002 (2)
O70.040 (2)0.0289 (18)0.053 (3)0.0000 (15)−0.002 (2)−0.0161 (18)
C80.019 (2)0.017 (2)0.042 (3)0.0062 (17)−0.002 (2)−0.005 (2)
C90.026 (2)0.018 (2)0.042 (3)0.0040 (17)−0.002 (2)−0.002 (2)
C100.024 (2)0.028 (2)0.053 (4)0.002 (2)−0.004 (2)−0.013 (2)
C110.025 (2)0.024 (2)0.041 (3)0.0109 (19)−0.010 (2)−0.012 (2)
C120.035 (3)0.023 (2)0.037 (3)0.007 (2)−0.002 (2)0.001 (2)
C130.022 (2)0.023 (2)0.048 (3)0.001 (2)−0.001 (2)0.000 (2)
F140.0400 (17)0.0448 (18)0.058 (2)0.0099 (15)−0.0234 (17)−0.0034 (17)
C150.0172 (19)0.0174 (19)0.025 (3)0.0021 (15)−0.0003 (18)−0.0017 (18)
C160.025 (2)0.022 (2)0.028 (3)0.0062 (18)0.000 (2)0.003 (2)
C170.029 (2)0.020 (2)0.030 (3)0.0014 (18)0.003 (2)0.006 (2)
N180.0232 (19)0.0212 (19)0.031 (3)0.0019 (15)0.0016 (17)−0.0046 (18)
C190.030 (2)0.025 (2)0.026 (3)0.0051 (19)−0.002 (2)0.000 (2)
C200.025 (2)0.018 (2)0.033 (3)0.0015 (18)−0.002 (2)0.0027 (19)
O210.049 (2)0.0213 (17)0.048 (3)−0.0046 (15)−0.0001 (19)−0.0107 (17)
C1—C21.360 (6)C10—H100.950
C1—C51.412 (7)C11—C121.354 (7)
C1—C81.489 (7)C11—F141.368 (6)
C2—N31.359 (6)C12—C131.388 (7)
C2—C151.472 (6)C12—H120.950
N3—O41.419 (5)C13—H130.950
N3—C61.444 (6)C15—C161.393 (6)
O4—C51.403 (6)C15—C201.394 (7)
C5—O71.218 (6)C16—C171.350 (7)
C6—H6A0.980C16—H160.950
C6—H6B0.980C17—N181.364 (7)
C6—H6C0.980C17—H170.950
C8—C91.389 (6)N18—O211.293 (5)
C8—C131.395 (7)N18—C191.366 (6)
C9—C101.391 (8)C19—C201.352 (7)
C9—H90.950C19—H190.950
C10—C111.382 (8)C20—H200.950
C2—C1—C5108.0 (4)C12—C11—F14118.8 (5)
C2—C1—C8128.4 (4)C12—C11—C10123.7 (5)
C5—C1—C8123.5 (4)F14—C11—C10117.5 (5)
N3—C2—C1110.5 (4)C11—C12—C13118.3 (5)
N3—C2—C15121.2 (4)C11—C12—H12120.9
C1—C2—C15128.3 (5)C13—C12—H12120.9
C2—N3—O4106.9 (4)C12—C13—C8121.0 (5)
C2—N3—C6129.5 (4)C12—C13—H13119.5
O4—N3—C6111.0 (4)C8—C13—H13119.5
C5—O4—N3107.6 (4)C16—C15—C20116.8 (4)
O7—C5—O4118.6 (5)C16—C15—C2123.5 (4)
O7—C5—C1134.9 (5)C20—C15—C2119.7 (4)
O4—C5—C1106.5 (4)C17—C16—C15121.6 (5)
N3—C6—H6A109.5C17—C16—H16119.2
N3—C6—H6B109.5C15—C16—H16119.2
H6A—C6—H6B109.5C16—C17—N18120.5 (4)
N3—C6—H6C109.5C16—C17—H17119.7
H6A—C6—H6C109.5N18—C17—H17119.7
H6B—C6—H6C109.5O21—N18—C17120.8 (4)
C9—C8—C13118.4 (5)O21—N18—C19120.2 (4)
C9—C8—C1121.4 (5)C17—N18—C19119.0 (4)
C13—C8—C1120.2 (4)C20—C19—N18121.3 (5)
C8—C9—C10121.5 (5)C20—C19—H19119.4
C8—C9—H9119.2N18—C19—H19119.4
C10—C9—H9119.2C19—C20—C15120.7 (4)
C11—C10—C9117.2 (5)C19—C20—H20119.6
C11—C10—H10121.4C15—C20—H20119.6
C9—C10—H10121.4
C5—C1—C2—N3−5.8 (6)C8—C9—C10—C110.2 (8)
C8—C1—C2—N3170.2 (5)C9—C10—C11—C120.0 (8)
C5—C1—C2—C15176.1 (4)C9—C10—C11—F14180.0 (4)
C8—C1—C2—C15−7.9 (8)F14—C11—C12—C13−179.7 (5)
C1—C2—N3—O47.4 (5)C10—C11—C12—C130.3 (8)
C15—C2—N3—O4−174.4 (4)C11—C12—C13—C8−0.9 (8)
C1—C2—N3—C6144.7 (5)C9—C8—C13—C121.1 (8)
C15—C2—N3—C6−37.1 (7)C1—C8—C13—C12178.5 (5)
C2—N3—O4—C5−6.0 (5)N3—C2—C15—C16−33.2 (7)
C6—N3—O4—C5−151.9 (4)C1—C2—C15—C16144.7 (5)
N3—O4—C5—O7−176.3 (5)N3—C2—C15—C20148.1 (5)
N3—O4—C5—C12.5 (5)C1—C2—C15—C20−34.1 (7)
C2—C1—C5—O7−179.6 (6)C20—C15—C16—C171.0 (6)
C8—C1—C5—O74.1 (10)C2—C15—C16—C17−177.8 (5)
C2—C1—C5—O41.9 (6)C15—C16—C17—N181.5 (7)
C8—C1—C5—O4−174.4 (4)C16—C17—N18—O21177.0 (4)
C2—C1—C8—C9−54.3 (8)C16—C17—N18—C19−3.1 (7)
C5—C1—C8—C9121.2 (5)O21—N18—C19—C20−177.9 (4)
C2—C1—C8—C13128.4 (6)C17—N18—C19—C202.2 (7)
C5—C1—C8—C13−56.1 (7)N18—C19—C20—C150.3 (7)
C13—C8—C9—C10−0.7 (8)C16—C15—C20—C19−1.9 (7)
C1—C8—C9—C10−178.1 (5)C2—C15—C20—C19176.9 (4)
  10 in total

1.  SHELXL: high-resolution refinement.

Authors:  G M Sheldrick; T R Schneider
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

2.  Substituted isoxazoles as potent inhibitors of p38 MAP kinase.

Authors:  Stefan A Laufer; Simona Margutti; Martina D Fritz
Journal:  ChemMedChem       Date:  2006-02       Impact factor: 3.466

3.  The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.

Authors:  Steven K Laughlin; Michael P Clark; Jane F Djung; Adam Golebiowski; Todd A Brugel; Mark Sabat; Roger G Bookland; Matthew J Laufersweiler; John C VanRens; Jennifer A Townes; Biswanath De; Lily C Hsieh; Susan C Xu; Richard L Walter; Marlene J Mekel; Michael J Janusz
Journal:  Bioorg Med Chem Lett       Date:  2005-05-02       Impact factor: 2.823

4.  An empirical correction for absorption anisotropy.

Authors:  R H Blessing
Journal:  Acta Crystallogr A       Date:  1995-01-01       Impact factor: 2.290

5.  SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

Authors:  L Revesz; F E Di Padova; T Buhl; R Feifel; H Gram; P Hiestand; U Manning; A G Zimmerlin
Journal:  Bioorg Med Chem Lett       Date:  2000-06-05       Impact factor: 2.823

6.  Potential of p38 inhibitors in the treatment of rheumatoid arthritis.

Authors:  M L Foster; F Halley; J E Souness
Journal:  Drug News Perspect       Date:  2000-10

7.  Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

Authors:  J L Adams; J C Boehm; S Kassis; P D Gorycki; E F Webb; R Hall; M Sorenson; J C Lee; A Ayrton; D E Griswold; T F Gallagher
Journal:  Bioorg Med Chem Lett       Date:  1998-11-17       Impact factor: 2.823

8.  Pyrroles and other heterocycles as inhibitors of p38 kinase.

Authors:  S E de Laszlo; D Visco; L Agarwal; L Chang; J Chin; G Croft; A Forsyth; D Fletcher; B Frantz; C Hacker; W Hanlon; C Harper; M Kostura; B Li; S Luell; M MacCoss; N Mantlo; E A O'Neill; C Orevillo; M Pang; J Parsons; A Rolando; Y Sahly; K Sidler; S J O'Keefe
Journal:  Bioorg Med Chem Lett       Date:  1998-10-06       Impact factor: 2.823

9.  Structural basis of inhibitor selectivity in MAP kinases.

Authors:  Z Wang; B J Canagarajah; J C Boehm; S Kassisà; M H Cobb; P R Young; S Abdel-Meguid; J L Adams; E J Goldsmith
Journal:  Structure       Date:  1998-09-15       Impact factor: 5.006

10.  From imidazoles to pyrimidines: new inhibitors of cytokine release.

Authors:  Stefan A Laufer; Gerd K Wagner
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.